Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 34.00%
March 31, 2026 37.96%
December 31, 2025 45.65%
September 30, 2025 42.97%
June 30, 2025 68.23%
March 31, 2025 58.07%
December 31, 2024 -16.54%
September 30, 2024 36.70%
June 30, 2024 62.24%
March 31, 2024 55.10%
December 31, 2023 59.41%
September 30, 2023 44.04%
June 30, 2023 52.31%
March 31, 2023 54.86%
December 31, 2022 69.64%
September 30, 2022 69.08%
June 30, 2022 45.37%
March 31, 2022 75.67%
December 31, 2021 78.26%
September 30, 2021 78.18%
June 30, 2021 78.68%
March 31, 2021 79.72%
December 31, 2020 78.91%
September 30, 2020 78.54%
June 30, 2020 78.34%
Date Value
March 31, 2020 77.22%
December 31, 2019 78.37%
September 30, 2019 77.18%
June 30, 2019 77.25%
March 31, 2019 76.38%
December 31, 2018 77.13%
September 30, 2018 75.23%
June 30, 2018 75.29%
March 31, 2018 75.37%
December 31, 2017 74.74%
September 30, 2017 74.46%
June 30, 2017 74.41%
March 31, 2017 75.80%
December 31, 2016 73.28%
September 30, 2016 73.58%
June 30, 2016 72.65%
March 31, 2016 72.20%
December 31, 2015 65.45%
September 30, 2015 64.26%
June 30, 2015 62.81%
March 31, 2015 63.41%
December 31, 2014 63.27%
September 30, 2014 60.60%
June 30, 2014 58.45%
March 31, 2014 59.30%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 95.87%
Alkermes Plc 75.30%
Liquidia Corp. 93.10%
Akari Therapeutics Plc --
DBV Technologies SA --

Gross Profit Margin (Quarterly) Related Metrics